全球双相情感障碍治疗市场 - 行业趋势及 2030 年预测

双相情感障碍治疗市场分析及规模

双相情感障碍是一种慢性精神疾病，其特征是情绪波动剧烈，包括躁狂和抑郁发作。全球双相情感障碍治疗市场包括各种药物、心理疗法和其他旨在管理和缓解该疾病症状的干预措施。数字医疗技术、远程医疗和移动应用程序用于心理健康监测和管理扩大了治疗选择，并增加了患者参与度。

Data Bridge Market Research 分析，全球双相情感障碍治疗市场在 2022 年为 52 亿美元，预计到 2030 年将达到 64.1025 亿美元，预计在 2023-2030 年预测期内的复合年增长率为 2.6%。这表明了市场价值。由于对更好的骨骼相关治疗方法的需求不断增长，“双相情感障碍 I”在全球双相情感障碍治疗市场的双相情感障碍类型部分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

双相情感障碍治疗市场范围和细分

Market Definition

The global bipolar disorder treatment market is the collective pharmaceuticals, therapies, and interventions aimed at managing and alleviating the symptoms and effects of bipolar disorder on a worldwide scale. Bipolar disorder, also known as manic-depressive illness, is a mental health condition characterized by extreme mood swings, including episodes of mania (elevated, high-energy mood) and depression (low, sad, or irritable mood). These mood swings can significantly impact a person's daily life, relationships, and overall well-being.

Global Bipolar Disorder Treatment Market Dynamics

Drivers

• Increasing Prevalence of Bipolar Disorder

The growing awareness and diagnosis of bipolar disorder have contributed to the expansion of the treatment market. Improved recognition of the condition has led to a higher demand for treatments.

• Advancements in Drug Development

Pharmaceutical companies have been actively investing in research and development to create more effective and targeted drugs for bipolar disorder. New drug formulations with fewer side effects and improved efficacy have emerged, attracting both patients and healthcare professionals.

Opportunity

• Increasing Healthcare Expenditure

As healthcare spending continues to rise in many countries, there is more financial support available for the diagnosis and treatment of mental health conditions, including bipolar disorder.

Restraint/Challenge

• Limited Access to Care

Disparities in access to mental healthcare, including shortages of mental health professionals and treatment facilities, can hinder timely and effective treatment for individuals with bipolar disorder, particularly in underserved areas.

Recent Development

• In September 2022, Otsuka America Pharmaceutical, Inc., (Otsuka) and H.Lundbeck A/S (Lundbeck) announced that the U.S. FDA approved their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of bipolar I disorder in adults. This approval helped the company to expand their customer base

Global Bipolar Disorder Treatment Market  Scope

The global bipolar disorder treatment market is segmented on the basis of bipolar disorder type, drug class, mechanism of action, route of administration, distribution channel and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Bipolar Disorders Type

• Bipolar I
• Bipolar II

Drug Class

• Anticonvulsants
• Antianxiety
• Mood Stabilizers
• Antipsychotic
• Antidepressant
• Others

Mechanism of Action

• Selective Serotonin Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitors
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Benzodiazepines
• Beta Blockers

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Bipolar Disorder Treatment Market Regional Analysis/Insights

The global bipolar disorder treatment market is analysed and market size insights and trends are provided by country, bipolar disorder type, drug class, mechanism of action, route of administration, distribution channel and end user as referenced above.

The countries covered in the global bipolar disorder treatment market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa

North America dominates the bone global bipolar disorder treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having bipolar disorders. 

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

报告的国家部分还提供了影响单个市场影响因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。  

医疗保健基础设施增长安装基础和新技术渗透

全球双相情感障碍治疗市场还为您提供了详细的市场分析，包括每个国家在资本设备医疗保健支出的增长情况、全球双相情感障碍治疗市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管场景的变化及其对全球双相情感障碍治疗市场的影响。

竞争格局和全球双相情感障碍治疗市场份额分析

全球双相情感障碍治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球双相情感障碍治疗市场的关注有关。

全球双相情感障碍治疗市场的一些主要参与者包括：

• 强生服务公司（美国）
• AbbVie Inc.（美国）
• 艾尔建（爱尔兰）
• 马林克罗德（爱尔兰）
• 太阳制药工业有限公司（印度）
• 诺华公司（瑞士）
• Endo Pharmaceuticals plc（爱尔兰）
• Zydus Cadila（印度）
• Mylan NV（美国）
• Mayne Pharma Group Limited（澳大利亚）
• 梯瓦制药工业有限公司 (以色列)
• Amneal Pharmaceutical Inc.（美国）
• Avet Pharmaceuticals Inc.（美国）
• Lannett（美国）
• Aurobindo Pharma（印度）
• Wockhardt（印度）
• Currax Pharmaceuticals LLC（美国）
• 阿斯利康（英国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 礼来公司 (美国)

SKU-26466